IRVINE, Calif., Oct. 17, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its third quarter 2012 financial results, which will take place on Thursday, October 25, 2012 after the close of the market.
Endologix will hold a conference call on Thursday, October 25, 2012 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and to provide updates on Endologix's operations and product pipeline. The dial-in numbers are (877) 407-0789 for domestic callers and (201) 689-8562 for international callers. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.endologix.com .
After the live webcast, a transcript of the call will remain available online from the investor relations page of Endologix's website, www.endologix.com , through November 25, 2012. In addition, a telephonic replay of the call will be available until November 1, 2012. The replay dial-in numbers are 877-870-5176 for domestic callers and 858-384-5517 for international callers. Please use the replay pin number 401535.About Endologix, Inc. Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. Endologix focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com .
CONTACT: COMPANY CONTACT: Endologix, Inc. John McDermott, CEO (949) 595-7200 www.endologix.com INVESTOR CONTACTS: The Ruth Group Nick Laudico (646) 536-7030 Zack Kubow (646) 536-7020